<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02621645</url>
  </required_header>
  <id_info>
    <org_study_id>S58224</org_study_id>
    <nct_id>NCT02621645</nct_id>
  </id_info>
  <brief_title>TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence</brief_title>
  <acronym>TRAPIST</acronym>
  <official_title>Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence: an Open-label Randomized Controlled Trial: TRAPIST - TRAP Intervention STudy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. George's Hospital, University of London (UK sponsor)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedalo Maggiore Policlinico di Milano, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari Vall d'hebron Barcelona, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Médico-Chirurgical et Obstétrical (CMCO) Schiltigheim, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinik für Frauenheilkunde und Geburtshilfe Graz, Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale dei Bambini &quot;Vittore Buzzi&quot; Milano, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Birmingham Women's Hospital, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sheba Medical Center Tel-Hashomer, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Memorial Hermann Hospital Houston Texas, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mount Sinai Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh School of Medicine, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Innsbruck, Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spedali Civili, University of Brescia, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center open-label randomized controlled trial to assess if early intervention
      (12.0-14.0 weeks) (study group) improves the outcome of TRAP sequence as compared to late
      intervention (16.0-19.0 weeks) (control group). The investigators will randomly assign women
      diagnosed with TRAP sequence diagnosed between 12.0 and 13.6 weeks to an early or late
      intervention group (1:1), using a web-based application and a computer-generated list with
      random permuted blocks of sizes 2 or 4 (www.sealedenvelope.com), stratified by gestational
      age (GA) at inclusion (11.6 -12.6 weeks versus 13.0-13.6 weeks). Analysis will be by
      intention to treat.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose to conduct a multi-center open-label randomized controlled trial to
      assess if early intervention (12.0-14.0 weeks) (study group) improves the outcome of TRAP
      sequence as compared to late intervention (16.0-19.0 weeks) (control group). The
      investigators will randomly assign women diagnosed with TRAP sequence diagnosed between 11.6
      and 13.6 weeks (1:1) to an early or late intervention group, using a web-based application
      (www.sealedenvelope.com) with a computer-generated list with random permuted blocks of sizes
      2 or 4, stratified by gestational age at inclusion (11.6 -12.6 weeks versus 13.0-13.6 weeks).
      Analysis will be by intention-to-treat. Outcome will be adjudicated blinded to group
      allocation.

      All interventions will be done under local anaesthesia and/or conscious sedation in sterile
      conditions by an experienced operator. They must be performed within 1 week after
      randomisation and at the latest at 14.0 weeks in the early group and 19.0 weeks in the late
      group. In the early group, only intrafetal coagulation will be used. Intrafetal ablation will
      be performed under ultrasound guidance using an 18-gauge (1.27 mm) to 20-gauge (0.91 mm)
      needle with a free-hand technique. The needle is introduced into the pelvis/abdomen of the
      TRAP mass close to the intra-abdominal portion of the feeding vessel, while avoiding puncture
      of the placenta and pump twin sac. The procedure is considered successful when there is
      complete cessation of reverse flow into the TRAP mass on intraoperative color-flow mapping.

      In the late intervention/control group either intrafetal coagulation or fetoscopic laser
      coagulation will be performed of the cord and/or anastomosing vessels, unless the flow has
      stopped spontaneously or demise of the pump twin has occurred in the meantime. Intrafetal
      coagulation is done as described above by using a 17-gauge (1.47 mm) to 20-gauge needle.
      Alternatively, fetoscopic laser coagulation of the cord or anastomosing vessels can be
      performed through a 17-gauge to 7 French trocar with 1-1,3 mm fetoscope and 400 μm laser
      fiber. The rationale not to standardize the technique in the late intervention group is that
      several techniques have been reported for treatment after 16 weeks without any significant
      differences in outcome. Also, it is usual for the surgeon to adapt the technique to the
      requirements of each individual case, e.g. for a posterior placenta, the surgeon may prefer
      fetoscopic rather than intrafetal coagulation. Not restricting the technique to only 1 option
      will therefore more truly represent current practice and increase the generalizability of the
      trial's findings.

      Patients will be discharged the same day or 1 day after the procedure. Management and
      follow-up will be similar for the study and the control or current practice group. A
      follow-up scan is usually performed 1 week after the intervention to check for fetal
      well-being and exclude anemia. A detailed ultrasound scan will be arranged in a fetal
      medicine center at 20 and 30 weeks to assess the heart and brain anatomy. Some centers may
      offer an MRI scan at around 30 weeks as part of the protocol for monochorionic twin
      pregnancies that underwent an intrauterine intervention. Antenatal, peripartum and postnatal
      care of the mother will be similar to that of a singleton pregnancy and at the discretion of
      the referring physician. Intrauterine intervention for TRAP sequence is not an indication for
      cesarean or elective preterm birth.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with neonatal survival and birth at or after 34.0 weeks of the pump twin</measure>
    <time_frame>2 weeks after expected date of birth</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with need for re-intervention</measure>
    <time_frame>2 weeks after expected date of birth</time_frame>
    <description>This means any kind of fetal intervention, such as repeated intrafetal coagulation, intra-uterine transfusion cord-occlusion...</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with maternal morbidity</measure>
    <time_frame>2 weeks after expected date of birth</time_frame>
    <description>Maternal morbidity is defined as presence of one or more of the following events:
Need for transfusion for hemorrhage
Abruption
Chorioamnionitis as defined on pathology
Sepsis
Bowel perforation
Other serious maternal morbidity requiring admission to ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with miscarriage</measure>
    <time_frame>2 weeks after expected date of birth</time_frame>
    <description>Number of patients with miscarriage before 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with preterm prelabor rupture of membranes (PPROM)</measure>
    <time_frame>2 weeks after expected date of birth</time_frame>
    <description>Number of patients with rupture of membranes before onset of labor and before 37 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with preterm birth prior to 28 weeks</measure>
    <time_frame>2 weeks after expected date of birth</time_frame>
    <description>Number of patients delivering before 28 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with preterm birth prior to 32 weeks</measure>
    <time_frame>2 weeks after expected date of birth</time_frame>
    <description>Number of patients delivering before 32 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with preterm birth prior to 37 weeks</measure>
    <time_frame>2 weeks after expected date of birth</time_frame>
    <description>Number of patients delivering before 37 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to delivery</measure>
    <time_frame>2 weeks after expected date of birth</time_frame>
    <description>Number of weeks between randomization and the time of delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to PPROM</measure>
    <time_frame>2 weeks after expected date of birth</time_frame>
    <description>Number of weeks between randomization and rupture of membranes in patients with PPROM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight in grams</measure>
    <time_frame>42 days (28 days neonatal period+2 weeks postdates) after expected date of birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with stillbirth</measure>
    <time_frame>42 days (28 days neonatal period+2 weeks postdates) after expected date of birth</time_frame>
    <description>Stillbirth refers to all patients with antepartum or intrapartum demise of the fetus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with neonatal death</measure>
    <time_frame>42 days (28 days neonatal period+2 weeks postdates) after expected date of birth</time_frame>
    <description>Demise of a live-born child within the first 28 days of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with severe neonatal morbidity</measure>
    <time_frame>42 days (28 days neonatal period+2 weeks postdates) after expected date of birth</time_frame>
    <description>Severe neonatal morbidity is defined as the presence of at least one of the following:
chronic lung disease (defined as oxygen dependency at 36 weeks gestational age)
patent ductus arteriosus needing medical therapy or surgical closure
necrotizing enterocolitis stage 2 or higher
retinopathy of prematurity stage 3 or higher
ischemic limb injury
amniotic band syndrome
severe cerebral injury (includes at least one of the following: intraventricular hemorrhage grade 3 or higher, cystic periventricular leukomalacia grade 2 or higher, ventricular dilatation greater than the 97th centile, porencephalic or parenchymal cysts or other severe cerebral lesions).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High volume vs low volume centers of neonatal survival and birth at or after 34.0 weeks of the pump twin and maternal morbidity parameters</measure>
    <time_frame>2 weeks after expected date of birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with intact survival rate</measure>
    <time_frame>2 years after expected date of birth</time_frame>
    <description>Intact survival rate defined as the number of surviving infants with normal development at two years corrected for prematurity as assessed by the ASQ® score for infant development (Ages &amp; Stages Questionnaire). A score of more than 2 standard deviations below the mean score for term-born children will be considered abnormal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with normal Bayley III score</measure>
    <time_frame>2 years after expected date of birth</time_frame>
    <description>Number of patients with normal Bayley III score at two years of age corrected for prematurity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Twin Reversal Arterial Perfusion Syndrome</condition>
  <arm_group>
    <arm_group_label>Early intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention between 12.0 and 14.0 weeks. Early selective reduction of TRAP mass.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention between 16.0 and 19.0 weeks. Late selective reduction of TRAP mass. This is the standard timing of the intervention. One of two possible techniques for late reduction is chosen by the treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Early selective reduction of TRAP mass</intervention_name>
    <description>Ultrasound-guided intrafetal ablation using an 18 Gauge to 20 Gauge needle</description>
    <arm_group_label>Early intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Late selective reduction of TRAP mass</intervention_name>
    <description>Ultrasound-guided intrafetal ablation using a 17 Gauge to 20 Gauge needle OR fetoscopic laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber. The treating physician can decide which technique will be used for the selective reduction.</description>
    <arm_group_label>Late intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound-guided intrafetal ablation using a 18 to 20 Gauge needle</intervention_name>
    <arm_group_label>Early intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound-guided intrafetal ablation using a 17 to 20 Gauge needle</intervention_name>
    <arm_group_label>Late intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber</intervention_name>
    <arm_group_label>Late intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TRAP sequence in a monochorionic diamniotic twin pregnancy diagnosed between 11.6 and
             13.6 weeks, as determined by the crown-rump length of the pump twin in spontaneous
             conceptions and by the date of insemination or embryonic age at replacement in
             pregnancies resulting from subfertility treatment

          -  Women aged 18 years or more, who are able to consent

          -  Anatomically normal pump twin

          -  Provide written informed consent to participate in this randomized controlled trial,
             forms being approved by the Ethical Committees

        Exclusion Criteria:

          -  Contraindication for an intervention due to a severe maternal medical condition or
             threatening miscarriage

          -  Inaccessibility of the acardiac twin due to a retroverted uterus, severe maternal
             obesity, uterine fibroids, bowel or placental superposition

          -  A major anomaly in the pump twin, requiring surgery or leading to infant death or
             severe handicap

          -  Spontaneous arrest of the reverse flow and/or pump twin demise at diagnosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liesbeth Lewi, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabel Couck, MD</last_name>
    <phone>+32 16 342294</phone>
    <email>isabel.couck@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liesbeth Lewi, MD PhD</last_name>
    <phone>+32 16 342862</phone>
    <email>liesbeth.lewi@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Johnson</last_name>
    </contact>
    <contact_backup>
      <last_name>Noemi Boring</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Klaritsch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liesbeth Lewi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Van Mieghem</last_name>
    </contact>
    <contact_backup>
      <last_name>Greg Ryan</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Médico-Chirurgical et Obstétrical</name>
      <address>
        <city>Schiltigheim</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain Favre</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Bamberg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoav Yinon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Persico</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale dei Bambini Vittore Buzzi</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariano Lanna</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dick Oepkes</last_name>
    </contact>
    <contact_backup>
      <last_name>Monique Haak</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlota Rodo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Women's Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Kilby</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Bower</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. George's Hospital, University of London (UK sponsor)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asma Khalil</last_name>
    </contact>
    <contact_backup>
      <last_name>Sarah Davies</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moore TR, Gale S, Benirschke K. Perinatal outcome of forty-nine pregnancies complicated by acardiac twinning. Am J Obstet Gynecol. 1990 Sep;163(3):907-12.</citation>
    <PMID>2206078</PMID>
  </reference>
  <reference>
    <citation>Pagani G, D'Antonio F, Khalil A, Papageorghiou A, Bhide A, Thilaganathan B. Intrafetal laser treatment for twin reversed arterial perfusion sequence: cohort study and meta-analysis. Ultrasound Obstet Gynecol. 2013 Jul;42(1):6-14. doi: 10.1002/uog.12495. Review.</citation>
    <PMID>23640771</PMID>
  </reference>
  <reference>
    <citation>Hecher K, Lewi L, Gratacos E, Huber A, Ville Y, Deprest J. Twin reversed arterial perfusion: fetoscopic laser coagulation of placental anastomoses or the umbilical cord. Ultrasound Obstet Gynecol. 2006 Oct;28(5):688-91.</citation>
    <PMID>16958150</PMID>
  </reference>
  <reference>
    <citation>Chaveeva P, Poon LC, Sotiriadis A, Kosinski P, Nicolaides KH. Optimal method and timing of intrauterine intervention in twin reversed arterial perfusion sequence: case study and meta-analysis. Fetal Diagn Ther. 2014;35(4):267-79. doi: 10.1159/000358593. Epub 2014 Apr 16.</citation>
    <PMID>24751835</PMID>
  </reference>
  <reference>
    <citation>Lewi L, Valencia C, Gonzalez E, Deprest J, Nicolaides KH. The outcome of twin reversed arterial perfusion sequence diagnosed in the first trimester. Am J Obstet Gynecol. 2010 Sep;203(3):213.e1-4. doi: 10.1016/j.ajog.2010.04.018. Epub 2010 Jun 3.</citation>
    <PMID>20522408</PMID>
  </reference>
  <reference>
    <citation>O'Donoghue K, Barigye O, Pasquini L, Chappell L, Wimalasundera RC, Fisk NM. Interstitial laser therapy for fetal reduction in monochorionic multiple pregnancy: loss rate and association with aplasia cutis congenita. Prenat Diagn. 2008 Jun;28(6):535-43. doi: 10.1002/pd.2025.</citation>
    <PMID>18509857</PMID>
  </reference>
  <reference>
    <citation>Scheier M, Molina FS. Outcome of twin reversed arterial perfusion sequence following treatment with interstitial laser: a retrospective study. Fetal Diagn Ther. 2012;31(1):35-41. doi: 10.1159/000334156. Epub 2011 Dec 23.</citation>
    <PMID>22204966</PMID>
  </reference>
  <reference>
    <citation>Berg C, Holst D, Mallmann MR, Gottschalk I, Gembruch U, Geipel A. Early vs late intervention in twin reversed arterial perfusion sequence. Ultrasound Obstet Gynecol. 2014 Jan;43(1):60-4. doi: 10.1002/uog.12578.</citation>
    <PMID>23908075</PMID>
  </reference>
  <reference>
    <citation>Jelin E, Hirose S, Rand L, Curran P, Feldstein V, Guevara-Gallardo S, Jelin A, Gonzales K, Goldstein R, Lee H. Perinatal outcome of conservative management versus fetal intervention for twin reversed arterial perfusion sequence with a small acardiac twin. Fetal Diagn Ther. 2010;27(3):138-41. doi: 10.1159/000295176. Epub 2010 Mar 9.</citation>
    <PMID>20215730</PMID>
  </reference>
  <reference>
    <citation>Lewi L, Gratacos E, Ortibus E, Van Schoubroeck D, Carreras E, Higueras T, Perapoch J, Deprest J. Pregnancy and infant outcome of 80 consecutive cord coagulations in complicated monochorionic multiple pregnancies. Am J Obstet Gynecol. 2006 Mar;194(3):782-9.</citation>
    <PMID>16522413</PMID>
  </reference>
  <reference>
    <citation>Kerstjens JM, Nijhuis A, Hulzebos CV, van Imhoff DE, van Wassenaer-Leemhuis AG, van Haastert IC, Lopriore E, Katgert T, Swarte RM, van Lingen RA, Mulder TL, Laarman CR, Steiner K, Dijk PH. The Ages and Stages Questionnaire and Neurodevelopmental Impairment in Two-Year-Old Preterm-Born Children. PLoS One. 2015 Jul 20;10(7):e0133087. doi: 10.1371/journal.pone.0133087. eCollection 2015.</citation>
    <PMID>26193474</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2015</study_first_submitted>
  <study_first_submitted_qc>December 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>monochorionic</keyword>
  <keyword>TRAP</keyword>
  <keyword>acardiac twin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

